Gyakuto
Senior Master
Researchers found that a single, carefully administered dose of psilocybin can produce rapid and sustained improvements in individuals with severe treatment-resistant depression, offering new hope when traditional therapies have failed.
pubmed.ncbi.nlm.nih.gov
The participants had tried at least five prior treatments without any improvement. Then, they received one 25-milligram dose of psilocybin alongside psychological support. Just three weeks after treatment, the changes were hard to deny. Nearly 70 percent of participants experienced a signification reduction in their symptoms, and 42 percent achieved complete remission.
The results indicated that the benefits lasted up to 3 months, suggesting one treatment could have long-term benefits. The treatment was well-tolerated with no serious adverse effects reported, underscoring its potential as a safe alternative for people with limited options.
Single-Dose Psilocybin for Depression With Severe Treatment Resistance: An Open-Label Trial - PubMed
This open-label study suggests efficacy and safety of psilocybin in severe TRD and supports further study of psychedelics in this population, including consideration of PTSD interaction effects.
pubmed.ncbi.nlm.nih.gov
The participants had tried at least five prior treatments without any improvement. Then, they received one 25-milligram dose of psilocybin alongside psychological support. Just three weeks after treatment, the changes were hard to deny. Nearly 70 percent of participants experienced a signification reduction in their symptoms, and 42 percent achieved complete remission.
The results indicated that the benefits lasted up to 3 months, suggesting one treatment could have long-term benefits. The treatment was well-tolerated with no serious adverse effects reported, underscoring its potential as a safe alternative for people with limited options.
